Galmed Pharmaceuticals (NASDAQ:EOCN – Get Free Report) will likely be posting its results on Wednesday, November 25th. Analysts expect Galmed Pharmaceuticals to post earnings of ($3.12) per share for the quarter.
Galmed Pharmaceuticals (NASDAQ:EOCN – Get Free Report) last posted its quarterly earnings data on Wednesday, September 2nd. The biopharmaceutical company reported ($2.86) earnings per share for the quarter, topping the consensus estimate of ($3.12) by $0.26.
Galmed Pharmaceuticals Trading Down 2.8%
NASDAQ:EOCN opened at $2.46 on Wednesday. Galmed Pharmaceuticals has a 52-week low of $2.05 and a 52-week high of $10.08. The stock has a 50-day simple moving average of $3.69 and a 200 day simple moving average of $4.49.
Analyst Upgrades and Downgrades
Read Our Latest Research Report on EOCN
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.
Read More
- Five stocks we like better than Galmed Pharmaceuticals
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
